ArticleTechnology in cancer research & treatment
Pain-Related PANoptosis Gene Signature Predicts Prognosis and Guides Therapy in Oral Squamous Cell Carcinoma.
Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionThis study aimed to develop a prognostic model based on pain-related PANoptosis genes to enhance therapeutic decision-making for oral squamous cell carcinoma (OSCC) patients.MethodsRNA sequencing data from 323 OSCC patients and 43 controls in the TCGA cohort were analyzed to identify differentially expressed genes (DEGs). Correlation analysis revealed pain-related PANoptosis genes, and a prognostic model was developed using Cox and LASSO regression and validated in the GSE42743 cohort. Immune microenvironment differences were assessed, and drug sensitivity was predicted. qRT-PCR was employed to validate gene expression alterations in OSCC tissues.ResultsAmong 2,253 DEGs, 38 overlapped with PANoptosis-related genes, leading to the identification of 37 pain-related PANoptosis genes that characterized two OSCC subtypes. A Pain-Related PANoptosis-gene model (including CA9, DEFB1, DES, IGLL5, LCE3D, LYNX1, SPINK7) achieved AUCs of 0.626 and 0.690 in the TCGA and validation cohorts, respectively. Significant immune microenvironment differences were noted, with high-risk patients showing immune characteristics associated with a more immunosuppressive environment. GSEA identified activated pathways like autophagy and chemokine signaling in high-risk patients.ConclusionsThe pain-related PANoptosis-gene model effectively stratifies OSCC patients by risk. Sepantronium bromide may represent a potential therapeutic candidate for high-risk patients; however, further experimental validation is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.